IL308225A - Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors - Google Patents
Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitorsInfo
- Publication number
- IL308225A IL308225A IL308225A IL30822523A IL308225A IL 308225 A IL308225 A IL 308225A IL 308225 A IL308225 A IL 308225A IL 30822523 A IL30822523 A IL 30822523A IL 308225 A IL308225 A IL 308225A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- tyrosine kinase
- combination therapies
- egfr tyrosine
- shp2
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184697P | 2021-05-05 | 2021-05-05 | |
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| PCT/US2022/027693 WO2022235815A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308225A true IL308225A (en) | 2024-01-01 |
Family
ID=83932546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308225A IL308225A (en) | 2021-05-05 | 2022-05-04 | Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220370456A1 (https=) |
| EP (1) | EP4334317A4 (https=) |
| JP (1) | JP2024516998A (https=) |
| AU (1) | AU2022270106A1 (https=) |
| CA (1) | CA3217092A1 (https=) |
| IL (1) | IL308225A (https=) |
| MX (1) | MX2023012929A (https=) |
| WO (1) | WO2022235815A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017216706A1 (en) * | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CA3048340A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) * | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| JP2024505680A (ja) * | 2021-02-05 | 2024-02-07 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| IL308222A (en) * | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| JP2024516997A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
-
2022
- 2022-05-04 MX MX2023012929A patent/MX2023012929A/es unknown
- 2022-05-04 CA CA3217092A patent/CA3217092A1/en active Pending
- 2022-05-04 EP EP22799518.0A patent/EP4334317A4/en active Pending
- 2022-05-04 JP JP2023567923A patent/JP2024516998A/ja active Pending
- 2022-05-04 IL IL308225A patent/IL308225A/en unknown
- 2022-05-04 US US17/736,869 patent/US20220370456A1/en active Pending
- 2022-05-04 AU AU2022270106A patent/AU2022270106A1/en active Pending
- 2022-05-04 WO PCT/US2022/027693 patent/WO2022235815A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516998A (ja) | 2024-04-18 |
| CA3217092A1 (en) | 2022-11-10 |
| WO2022235815A1 (en) | 2022-11-10 |
| EP4334317A1 (en) | 2024-03-13 |
| EP4334317A4 (en) | 2025-03-05 |
| AU2022270106A1 (en) | 2023-12-14 |
| MX2023012929A (es) | 2023-11-13 |
| US20220370456A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202109067PA (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| IL281805A (en) | Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use | |
| PT3911648T (pt) | 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização | |
| IL279587A (en) | Protein tyrosine phosphatase inhibitors and methods of using them | |
| SG11202107615TA (en) | Pcsk9 inhibitors and methods of use thereof | |
| EP3906061A4 (en) | METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE | |
| GB2591931B (en) | Systems and methods for privacy preserving determination of intersections of sets of user identifiers | |
| IL280632A (en) | Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors | |
| IL320829A (en) | PARP1 inhibitors and their uses | |
| HUE069020T2 (hu) | Eljárások Sjögren-szindróma kezelésére Bruton-féle tirozinkináz gátlószerének alkalmazásával | |
| IL286983A (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| SG11202104609SA (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| IL326872A (en) | EGFR allosteric inhibitors and methods of using them | |
| IL287962A (en) | Combined treatments with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
| ZA202200834B (en) | Isoquinolinone derivatives serving as rock protein kinase inhibitors and use thereof | |
| IL326776A (en) | Combinations comprising a BCR:ABL-1 inhibitor and a second tyrosine kinase inhibitor for use in the treatment of cancer | |
| IL308225A (en) | Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors | |
| IL255582A (en) | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors | |
| PT3902548T (pt) | Inibidor de egfr resistente a tratamento mutante l718 e/ou l792 para utilização no tratamento de cancro | |
| ZA202103278B (en) | Crystal form of maleate of tyrosine kinase inhibitor and preparation method therefor | |
| EP4097140A4 (en) | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS | |
| IL315365A (en) | Spleen tyrosine kinase inhibitor, composition and methods of use | |
| IL318327A (en) | Tyrosine kinase 2 inhibitors and their uses | |
| IL286699A (en) | Atypical protein c kinase inhibitors and their use in the treatment of hedgehog pathway-dependent cancers | |
| IL315848A (en) | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |